Measuring psoriatic disease in clinical practice. An expert opinion position paper
Copyright © 2015 Elsevier B.V. All rights reserved..
Psoriasis is a common, immune-mediated chronic inflammatory disease with a primary involvement of skin and joints, affecting approximately 2% of the population worldwide. Up to one third of patients with psoriasis are diagnosed with psoriatic arthritis (PsA). Psoriasis and PsA are heterogeneous diseases whose severity depends on a number of clinical factors, such as areas affected and pattern of involvement, and are associated with a range of comorbid diseases and risk factors, including obesity, metabolic syndrome, cardiovascular disease and liver disease. Thus measuring the severity of psoriatic disease needs to take into account the multidimensional aspects of the disease. Subjective measures including the impairment in quality of life or in daily living activities as well as the presence of cardio-metabolic comorbidities, are important for the outcome and add further levels of complexity that, to a certain extent, need to be assessed. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented for a most effective managing of psoriasis patients. A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively. Our objective was to provide an expert position on which clinical variables are to be taken into account when considering patients affected by psoriasis and/or PsA globally and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 14(2015), 10 vom: 05. Okt., Seite 864-74 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lubrano, Ennio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular |
|---|
| Anmerkungen: |
Date Completed 04.01.2016 Date Revised 02.12.2018 published: Print-Electronic ErratumIn: Autoimmun Rev. 2016 Jan;15(1):112 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2015.05.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM24948451X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM24948451X | ||
| 003 | DE-627 | ||
| 005 | 20231224153658.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2015.05.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0831.xml |
| 035 | |a (DE-627)NLM24948451X | ||
| 035 | |a (NLM)26025585 | ||
| 035 | |a (PII)S1568-9972(15)00118-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lubrano, Ennio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Measuring psoriatic disease in clinical practice. An expert opinion position paper |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Autoimmun Rev. 2016 Jan;15(1):112 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier B.V. All rights reserved. | ||
| 520 | |a Psoriasis is a common, immune-mediated chronic inflammatory disease with a primary involvement of skin and joints, affecting approximately 2% of the population worldwide. Up to one third of patients with psoriasis are diagnosed with psoriatic arthritis (PsA). Psoriasis and PsA are heterogeneous diseases whose severity depends on a number of clinical factors, such as areas affected and pattern of involvement, and are associated with a range of comorbid diseases and risk factors, including obesity, metabolic syndrome, cardiovascular disease and liver disease. Thus measuring the severity of psoriatic disease needs to take into account the multidimensional aspects of the disease. Subjective measures including the impairment in quality of life or in daily living activities as well as the presence of cardio-metabolic comorbidities, are important for the outcome and add further levels of complexity that, to a certain extent, need to be assessed. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented for a most effective managing of psoriasis patients. A joint dermatologist-rheumatologist roundtable discussion was convened to share evidence on the real-life use of methods for measuring psoriasis severity comprehensively. Our objective was to provide an expert position on which clinical variables are to be taken into account when considering patients affected by psoriasis and/or PsA globally and on the assessment tools more suitable for measuring disease activity and/or severity in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cardiovascular | |
| 650 | 4 | |a Comorbidities | |
| 650 | 4 | |a Metabolic syndrome | |
| 650 | 4 | |a Outcome measures | |
| 650 | 4 | |a Psoriasis | |
| 650 | 4 | |a Psoriatic arthritis | |
| 700 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Girolomoni, Giampiero |e verfasserin |4 aut | |
| 700 | 1 | |a Prignano, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Ignazio |e verfasserin |4 aut | |
| 700 | 1 | |a Scarpa, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Spadaro, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 700 | 1 | |a Narcisi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Ricceri, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Sarzi-Puttini, Piercarlo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 14(2015), 10 vom: 05. Okt., Seite 864-74 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2015 |g number:10 |g day:05 |g month:10 |g pages:864-74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2015.05.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2015 |e 10 |b 05 |c 10 |h 864-74 | ||